6-80168906-G-C
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_183050.4(BCKDHB):āc.509G>Cā(p.Arg170Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000434 in 1,613,930 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_183050.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BCKDHB | NM_183050.4 | c.509G>C | p.Arg170Pro | missense_variant | 5/10 | ENST00000320393.9 | NP_898871.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BCKDHB | ENST00000320393.9 | c.509G>C | p.Arg170Pro | missense_variant | 5/10 | 1 | NM_183050.4 | ENSP00000318351 | P1 | |
BCKDHB | ENST00000356489.9 | c.509G>C | p.Arg170Pro | missense_variant | 5/11 | 1 | ENSP00000348880 | P1 | ||
BCKDHB | ENST00000369760.8 | c.509G>C | p.Arg170Pro | missense_variant | 5/6 | 3 | ENSP00000358775 |
Frequencies
GnomAD3 genomes AF: 0.00000658 AC: 1AN: 152076Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251426Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135888
GnomAD4 exome AF: 0.00000410 AC: 6AN: 1461854Hom.: 0 Cov.: 34 AF XY: 0.00000413 AC XY: 3AN XY: 727232
GnomAD4 genome AF: 0.00000658 AC: 1AN: 152076Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74288
ClinVar
Submissions by phenotype
Maple syrup urine disease Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 12, 2022 | This sequence change replaces arginine, which is basic and polar, with proline, which is neutral and non-polar, at codon 170 of the BCKDHB protein (p.Arg170Pro). This variant is present in population databases (rs371518124, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with BCKDHB-related conditions. ClinVar contains an entry for this variant (Variation ID: 96592). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). This variant disrupts the p.Arg170 amino acid residue in BCKDHB. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 22326532; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 13, 2022 | The c.509G>C (p.R170P) alteration is located in exon 5 (coding exon 5) of the BCKDHB gene. This alteration results from a G to C substitution at nucleotide position 509, causing the arginine (R) at amino acid position 170 to be replaced by a proline (P). Based on data from gnomAD, the C allele has an overall frequency of <0.01% (5/251426) total alleles studied. The highest observed frequency was 0.01% (5/34592) of Latino alleles. This variant was identified as homozygous in an individual affected with Maple syrup urine disease (Clinvar database). In addition, multiple different variants at this position have been described in patients with Maple syrup urine disease including p.R170H, p.R170C, and p.R170G (Li, 2018; Abiri, 2019; Strauss, 2020; O'Reilly, 2021). Based on internal structural analysis, the p.R170P variant was determined to be more destabilizing than these previously reported variants (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. - |
BCKDHB-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 03, 2024 | The BCKDHB c.509G>C variant is predicted to result in the amino acid substitution p.Arg170Pro. To our knowledge, this variant has not been reported in the literature. However, alternate nucleotide substitutions affecting the same amino acid (p.Arg170Cys, p.Arg170His, and p.Arg170Gly) have been reported in the homozygous and compound heterozygous states in multiple individuals with maple syrup urine disease (see for example, Miryounesi et al. 2015. PubMed ID: 25381949; Table 3, OReilly et al. 2020. PubMed ID: 33300147; Table S1, Strauss et al. 2020. PubMed ID: 31980395). The p.Arg170 amino acid has been highly evolutionarily conserved (Alamut Visual v2.11). In silico analysis suggested that the p.Arg170 residue is in close proximity to the K+ binding site in the branched-chain alpha-ketoacid dehydrogenase (BCKD) enzyme complex, and that substitutions of this amino acid may cause unstable dimer assembly and an unstable K+ ion binding loop (Miryounesi et al. 2015. PubMed ID: 25381949). This variant is reported in 0.014% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as likely pathogenic. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 31, 2012 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at